News | Left Atrial Appendage (LAA) Occluders | December 29, 2015

American College of Cardiology Launches Left Atrial Appendage Occlusion Registry

Registry will track use, results of new stroke prevention technology in atrial fibrillation patients

watchman LAA occluder, LAAO registry

Implantation of the Boston Scientific Watchman LAA occluder.

December 29, 2015 — The American College of Cardiology (ACC) launched the new Left Atrial Appendage Occlusion (LAAO) Registry Dec. 16. It will to capture data on a new class of medical devices used in left atrial appendage (LAA) occlusion procedures.

The LAA is a muscular pouch connected to the left atrium of the heart where blood can gather and lead to blood clots that can cause stroke in patients with atrial fibrillation. Left atrial appendage occlusion or closure procedures and devices can reduce stroke risk as an alternative to anticoagulation with medications among patients with non-valvular atrial fibrillation.

The LAAO Registry will help assess real-world procedural indications and outcomes as well as short- and long-term safety of procedures and devices for closing the left atrial appendage.  Paul D. Varosy, M.D., FACC, FAHA, FHRS, who is director of cardiac EP at VA Eastern Colorado Health Care System, is the lead physician for the data set development work group for the LAAO Registry.

The registry will serve not only as the formal FDA-mandated post-approval study for the Boston Scientific Watchman device, but it is also expected to serve as a long-term clinical registry for all patients undergoing occlusion of the left atrial appendage, regardless of the device used.

“It is exciting that we are launching this registry at the beginning of implementation of this transformative therapy,” Varosy said. “Clinicians, hospitals, payers, and especially patients will benefit from a clear understanding of how these devices are being used in real-world practice. A registry like this can provide important tools in ensuring that the quality of care is as high as it can be for patients receiving these devices.”

The new clinical registry program joins eight other programs that comprise the National Cardiovascular Data Registry, the ACC's suite of cardiovascular data registries that help hospitals and clinical practices measure and improve the quality of care they provide. Additionally, an atrial fibrillation ablation registry, officially the AFib Ablation Registry, is expected to launch in 2016.

For more information:

Related Content

Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors


News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Ticagrelor Has Comparable Safety to Clopidogrel after Heart Attack

Image from presentation, "Ticagrelor Versus Clopidogrel After Thrombolytic Therapy in Patients With St-Elevation Myocardial Infarction: A Randomized Clinical Trial," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Among people younger than 75 years who were given clot busters to treat a heart attack, taking the m
Overlay Init